ICYMI: GALLUP FINDS NEARLY 58 MILLION AMERICANS UNABLE TO AFFORD THEIR PRESCRIPTION DRUGS, UP FOUR PERCENT FROM JANUARY

11-13-2019 Blog Posts

Nine in Ten Surveyed Adults Believe Rx Prices “Much Higher” Or “Somewhat Higher” Than Reasonable A new Gallup survey demonstrates the rising toll of out-of-control prescription drug prices on American patients and families. According to the survey, nearly 23 percent of Americans, approaching 58 million U.S. adults, say they have been unable to afford drugs […]

SECOND OPINION: BIG PHARMA SQUARELY TO BLAME FOR RISING MEDICARE PREMIUMS

11-12-2019 Blog Posts

Drug Makers Cry ‘False Narrative’ Over Latest Repot Highlighting Toll of the Industry’s Egregious Pricing Practices Last week, the Centers for Medicare & Medicaid Services (CMS) released a new report attributing premium increases for Medicare Part B beneficiaries to rising drug prices. Like clockwork, Big Pharma immediately attempted to evade responsibility by claiming that “the […]

Q3 Earnings: Big Pharma Keeps The Good Times Rolling While Hiking Prices

11-7-2019 Blog Posts

Q3 Earnings: Big Pharma Keeps The Good Times Rolling While Hiking Prices Top Brand Name Drug Makers Best Earnings Forecasts While Evading Accountability And that’s a wrap! Three weeks of earnings calls have proven, yet again, that Big Pharma’s top concern is padding their bottom line and keeping a profit gravy train running – not […]

AMERICANS AGREE: CONGRESS MUST ACT TO HOLD BIG PHARMA ACCOUNTABLE AND LOWER DRUG PRICES

11-4-2019 Blog Posts

Solutions to Reform Medicare Part D, Increase Competition and Boost Transparency Have Broad Bipartisan Support, Should Be Swiftly Passed THE CRISIS OF RISING PRESCRIPTION DRUG PRICES The anti-competitive tactics and price-gouging practices of Big Pharma have created a crisis of prescription drug affordability in America. Today, as many as one-in-four Americans are unable to afford […]

Big Pharma Earnings Watch: Abbvie

11-1-2019 Blog Posts

Brand Name Drug Giant Completes Sweep of Big Pharma Companies Who Beat Expectations After Hiking Prices Earnings reports for the third quarter of the year provide the latest evidence that Big Pharma continues to bank record profits while price-gouging American patients. Today, brand name drug giant AbbVie announced better than expected earnings after a year […]

BIG PHARMA EARNINGS WATCH: BRISTOL-MYERS SQUIBB AND SANOFI

10-31-2019 Blog Posts

Good Times Rolling for Brand Name Drug Makers, Two More Top Earnings Forecasts After Increasing Prices Two more brand name giants – Bristol-Myers Squibb and Sanofi – topped earnings expectations while continuing to hike prices on vulnerable patients. The pair keep a trend alive that’s been consistent for all nine of the world’s largest pharmaceutical […]

Big Pharma Earnings Watch: Glaxosmithkline and Amgen

10-30-2019 Blog Posts

Big Pharma’s Earnings Keep Rising Off of Price Hikes To no one’s surprise, two more brand name drug manufacturers, GlaxoSmithKline (GSK) and Amgen both topped earnings expectations for the third quarter of 2019 this week after hiking prices on their products earlier this year. Of the Big Pharma giants who have announced Q3 earnings so […]

Big Pharma Watch: Merck and Pfizer

10-29-2019 Blog Posts

Two More Big Pharma Giants Beat Q3 Forecasts After Hiking Prices On Cancer And Arthritis Drugs Kicking off the final week of Q3 earnings reports, two more brand name giants – Merck and Pfizer – both “easily” beat Wall Street expectations after hiking prices on American patients earlier this year. Merck Merck reported $12.4 billion […]

Big Pharma Earnings Watch: Eli Lilly

10-24-2019 Blog Posts

Pharmaceutical Giant Beats Q3 Profit Forecasts After Hiking Prices on Drugs Used to Treat Diabetes and Cancer Yesterday, Eli Lilly joined fellow Big Pharma giants Johnson & Johnson, Roche and Novartis in surpassing earnings expectations for the third quarter of 2019 — after continuing to hike prices on its medications despite the rising crisis of […]

Big Pharma Earnings Watch: Astrazeneca

10-24-2019 Blog Posts

Another Brand Name Drug Maker Beats Expectations After Raising Prices Rounding out this week’s reporting on third quarter earnings, Big Pharma giant AstraZeneca joined four other brand name giants in beating expectations after raising prices on their products earlier this year. AstraZeneca reported $6.1 billion in revenue, beating expectations of $5.8 billion. The company raised […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.